Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Alder BioPharmaceuticals to related companies based on the strength of its earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Earnings & Valuation
This table compares Alder BioPharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Alder BioPharmaceuticals||$110,000.00||-$156.25 million||-2.14|
|Alder BioPharmaceuticals Competitors||$290.27 million||$35.99 million||66.50|
Alder BioPharmaceuticals’ competitors have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
96.8% of Alder BioPharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.6% of Alder BioPharmaceuticals shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Alder BioPharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alder BioPharmaceuticals Competitors||897||3302||11792||236||2.70|
Alder BioPharmaceuticals presently has a consensus price target of $30.58, suggesting a potential upside of 167.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.27%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Alder BioPharmaceuticals is more favorable than its competitors.
Risk & Volatility
Alder BioPharmaceuticals has a beta of 2.48, meaning that its share price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ competitors have a beta of 6.13, meaning that their average share price is 513% more volatile than the S&P 500.
This table compares Alder BioPharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alder BioPharmaceuticals Competitors||-5,189.81%||-162.78%||-35.24%|
Alder BioPharmaceuticals competitors beat Alder BioPharmaceuticals on 7 of the 13 factors compared.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.